Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases

Collaboration advances Silence's proprietary platform in the growing field of RNAi technology

Agreement provides Mallinckrodt with an exclusive worldwide license for one preclinical asset that targets a specific protein in the complement pathway, C3 (SL... Biopharmaceuticals, Licensing Mallinckrodt, Silence Therapeutics

Source: HSMN NewsFeed - July 18, 2019 Category: Pharmaceuticals Source Type: news